Transmitted HIV-1 Drug Resistance Among Newly Diagnosed Individuals in 31 Provincial-Level Administrative Divisions in China in 2023: A Cross-sectional Survey
Clinical Infectious Diseases·
- DOI
- 10.1093/cid/ciaf159
- PMID
- 40295173
- PMCID
- —
- OpenAlex
- W4409877409
- Study type
- Cross-sectional study
- Publisher
- Oxford University Press (OUP)
- Article type
- journal-article
- Integrity
- current
Why this research matters now
TDR prevalence exceeding 10%, including >5% to efavirenz/nevirapine, suggests a need for ongoing surveillance and consideration of regimen selection in newly diagnosed populations in China.
Structured evidence summary
Research question
The study assessed the prevalence and correlates of transmitted HIV-1 drug resistance among individuals newly diagnosed with HIV across 31 provincial-level divisions of China.
Study design
A cross-sectional survey conducted between April and June 2023, with demographic data and plasma collected at HIV diagnosis; partial pol sequences were analyzed using the Stanford HIV drug resistance database and HIV-TRACE, and logistic regression identified factors associated with transmitted drug resistance.
Population and setting
Individuals newly diagnosed with HIV across 31 provincial-level administrative divisions in China during a three-month window in 2023, with successful HIV drug resistance genotyping performed on 6,654 participants.
Main findings
Overall transmitted drug resistance prevalence was 11.4% (95% CI 10.6%-12.2%). Class-specific resistance was 7.9% to NNRTIs, 0.8% to NRTIs, 2.4% to PIs, and 1.0% to INSTIs, with efavirenz/nevirapine resistance at 6.5%. In adjusted analysis, non-Han ethnicity, unknown transmission route, and CD4 ≥500 cells/μL were associated with higher TDR odds, while higher education was associated with lower odds.
Public-health relevance
TDR prevalence exceeding 10%, including >5% to efavirenz/nevirapine, suggests a need for ongoing surveillance and consideration of regimen selection in newly diagnosed populations in China.
Important limitations
The summary is limited to the supplied single-article abstract and metadata; limitations such as representativeness of the three-month sampling window, completeness of self-reported transmission route, and generalizability beyond 2023 are not detailed in the abstract and require review of the original paper for decision-grade interpretation.
GIDS interpretation
This peer-reviewed cross-sectional survey is discoverable through classifiers linking it to HIV/AIDS surveillance, transmission dynamics, and treatment in China, providing a contextual snapshot of transmitted resistance patterns; the abstract does not connect findings to any live surveillance signal.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 11 auditable classifier relationships to diseases, places, topics, and study design.